Peficitinib

Drug Profile

Peficitinib

Alternative Names: ASP-015K; ASP-015K hydrobromide; JNJ-54781532; Peficitinib hydrobromide

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Adamantanes; Amides; Antipsoriatics; Antirheumatics; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Transplant rejection; Ulcerative colitis

Most Recent Events

  • 01 Dec 2016 Astellas Pharma completes a phase I trial in pharmacokinetics trial in Japan (PO) (NCT02603497)
  • 01 Sep 2016 Astellas Pharma completes a phase I pharmacokinetics trial in Japan (PO) (NCT02586194)
  • 30 Jun 2016 Astellas Pharma completes a phase I drug-drug interaction trial in Healthy volunteers in Japan (PO) (NCT02760342)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top